There is considerable interest in developing new quantitative imaging methods to monitor and predict breast cancer response to neoadjuvant chemotherapy (NAC), both prior to and as early as possible during the course of treatment. Diffuse optical spectroscopic imaging (DOSI) allows patients to be followed from baseline through treatment and surgery with a cost-effective, bedside, handheld scanning probe. In this competing renewal application, we propose to further advance the development of a standardized DOSI technology platform by introducing a new, portable, miniature device (m-DOSI) that has significantly reduced cost and size with equivalent performance compared to existing instruments. m-DOSI scanners will be constructed and delivered to all collaborating clinical sites and up to 150 pre-surgical NAC patients will be evaluated in multi- center studies. Our goal is to establish quantitative DOSI functional endpoints of NAC response that predict patient clinical outcome as measured by pathologic complete response (pCR). In order to optimize the power of DOSI predictions and ease of integration into the clinical work flow, we propose to validate three measurement time-points and DOSI endpoints first discovered in our current funding cycle: 1) Tissue oxygen saturation prior to chemotherapy infusion, 2) Tissue oxyhemoglobin concentration one day following the first infusion, and 3) a Tissue optical index (TOI) at the midpoint of NAC prior to switching drug regimens. Tumor hemodynamics will also be investigated during the first week of therapy. NAC midpoint response is currently undergoing evaluation as part of our American College of Radiology Imaging Network 60-patient multi-center clinical trial (ACRIN-6691) that completed enrollment in March 2013, two months prior to the originally anticipated June 2013 end date. We hypothesize that the combination of pre-therapy and one-day post- infusion measurements with the ACRIN mid-point assessment will provide a more practical and improved approach for managing patients. In order to develop new insight into achieving pCR in the challenging triple negative (TN) breast cancer population we will stratify response by molecular subtype and adjust our multi- endpoint predictive model for the TN subgroup. Finally, we will continue to optimize and improve m-DOSI functionality, standardize clinical measurement and analysis procedures, and evaluate whether m-DOSI can be used with equivalent overall performance by different operators. Our long-term goal is to identify the right combination of quantitative clinical endpoints for informing medical decisions on chemotherapy regimen, duration, and timing of surgery. Ultimately this work is expected to lead to a bedside optical imaging technology that can be used to improve patient outcome by maximizing therapeutic response, minimizing unnecessary toxicity, and optimizing clinical decision-making.

Public Health Relevance

Developing DOSI Technology for Monitoring Response to Breast Cancer Chemotherapy Competing Continuation A1 Resubmission Application: 1R01CA142989 Narrative We propose to advance the development of a portable, bedside optical imaging technology capable of monitoring and predicting patient response to breast cancer neoadjuvant chemotherapy. The technology, Diffuse Optical Spectroscopic Imaging (DOSI), will be evaluated in a multi-center study designed to validate optical endpoints of clinica response.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA142989-04A1
Application #
8652204
Study Section
Special Emphasis Panel (ZRG1-SBIB-Z (03))
Program Officer
Henderson, Lori A
Project Start
2010-01-01
Project End
2017-12-31
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
4
Fiscal Year
2014
Total Cost
$577,440
Indirect Cost
$192,216
Name
University of California Irvine
Department
None
Type
Organized Research Units
DUNS #
046705849
City
Irvine
State
CA
Country
United States
Zip Code
92697
Hou, Jue; Wright, Heather J; Chan, Nicole et al. (2016) Correlating two-photon excited fluorescence imaging of breast cancer cellular redox state with seahorse flux analysis of normalized cellular oxygen consumption. J Biomed Opt 21:60503
Leproux, Anaïs; Kim, You Me; Min, Jun Won et al. (2016) Differential diagnosis of breast masses in South Korean premenopausal women using diffuse optical spectroscopic imaging. J Biomed Opt 21:74001
Tromberg, Bruce J; Zhang, Zheng; Leproux, Anaïs et al. (2016) Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging. Cancer Res 76:5933-5944
O'Sullivan, Thomas D; Leproux, Anaïs; Chen, Jeon-Hor et al. (2013) Optical imaging correlates with magnetic resonance imaging breast density and reveals composition changes during neoadjuvant chemotherapy. Breast Cancer Res 15:R14
Roblyer, Darren; O'Sullivan, Thomas D; Warren, Robert V et al. (2013) Feasibility of Direct Digital Sampling for Diffuse Optical Frequency Domain Spectroscopy in Tissue. Meas Sci Technol 24:045501
Leproux, Anaïs; Durkin, Amanda; Compton, Montana et al. (2013) Assessing tumor contrast in radiographically dense breast tissue using Diffuse Optical Spectroscopic Imaging (DOSI). Breast Cancer Res 15:R89
O'Sullivan, Thomas D; Cerussi, Albert E; Cuccia, David J et al. (2012) Diffuse optical imaging using spatially and temporally modulated light. J Biomed Opt 17:071311
Thayer, David A; Lin, Yuting; Luk, Alex et al. (2012) Laser-induced photo-thermal magnetic imaging. Appl Phys Lett 101:83703
Cerussi, Albert E; Warren, Robert; Hill, Brian et al. (2012) Tissue phantoms in multicenter clinical trials for diffuse optical technologies. Biomed Opt Express 3:966-71
Lin, Yuting; Bolisay, Linden; Ghijsen, Michael et al. (2012) Temperature-modulated fluorescence tomography in a turbid media. Appl Phys Lett 100:73702-737024

Showing the most recent 10 out of 27 publications